EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair

Fanying Meng iD, Tianyang Qi, Xing Liu, Yizhi Wang, Jibing Yu, Zhaoqiang Lu, Xiaohong Cai, Anrong Li, Don Jung, Jianxin Duan

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Fanying Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ascentawits Pharmaceuticals, LTD, Shenzhen, China. Hauptthemen laut MEDLINE: Prodrugs, DNA Repair, Aldo-Keto Reductase Family 1 Member C3, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Development and Reform Commission of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AST‐3424 is a novel and highly tumor‐selective prodrug. AST‐3424 is activated by AKR1C3 to release a toxic bis‐alkylating moiety, AST 2660. In this study, we have investigated the essential role of DNA repair in AST‐3424 mediated pharmacological activities in vitro and in vivo . We show here that AST‐3424 is effective as a single therapeutic agent against cancer cells to induce cytotoxicity, DNA damage, apoptosis and cell cycle arrest at G2 phase in a dose‐ and AKR1C3‐dependent manner in both p53‐proficient H460 (RRID:CVCL_0459) and p53‐deficient HT‐29 cells (RRID:CVCL_0320). The combination of abrogators of G2 checkpoint with AST‐3424 was only synergistic in HT‐29 but not in H460 cells. The enhanced activity of AST‐3424 in HT‐29 cells was due to impaired DNA repair ability via the attenuation of cell cycle G2 arrest and reduced RAD51 expression. Furthermore, we utilized a BRCA2 deficient cell line and two PDX models with BRCA deleterious mutations to study the increased activity of AST‐3424. The results showed that AST‐3424 exhibited enhanced in vitro cytotoxicity and superior and durable in vivo anti‐tumor effects in cells deficient of DNA repair protein BRCA2. In summary, we report here that when DNA repair capacity is reduced, the in vitro and in vivo activity of AST‐3424 can be further enhanced, thus providing supporting evidence for the further evaluation of AST‐3424 in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsDNA RepairAldo-Keto Reductase Family 1 Member C3Xenograft Model Antitumor AssaysApoptosisHumansAnimalsMiceHT29 CellsDNA DamageCell Line, TumorAntineoplastic AgentsG2 Phase Cell Cycle CheckpointsNeoplasms

Stichwörter der Autor:innen

AKR1C3AST‐3424DNA repaircell cyclesp53

Substanzen

ProdrugsAldo-Keto Reductase Family 1 Member C3AKR1C3 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Ascentawits Pharmaceuticals, LTD, Shenzhen, China.

ORCID-Profile: Fanying Meng

Förderung

  • Development and Reform Commission of Shenzhen Municipality

Zitieren

APA

Meng, F., Qi, T., Liu, X., Wang, Y., Yu, J., Lu, Z., Cai, X., Li, A., Jung, D., & Duan, J. (2025). Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair. International Journal of Cancer. https://doi.org/10.1002/ijc.35170

Vancouver

Meng F, Qi T, Liu X, Wang Y, Yu J, Lu Z, et al. Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair. International Journal of Cancer. 2025. doi:10.1002/ijc.35170

BibTeX
@article{Meng2025,
  author = {Meng, Fanying and Qi, Tianyang and Liu, Xing and Wang, Yizhi and Yu, Jibing and Lu, Zhaoqiang and Cai, Xiaohong and Li, Anrong and Jung, Don and Duan, Jianxin},
  title = {Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35170}
}
Kostenlos starten →